Clinical Research Directory

Inclusion Criteria: * Males or females aged 18 to 75 years; * Histologically or cytologically confirmed esophageal or esophageal-gastric junction squamous cell carcinoma; * Patients who have not received prior systemic anti-tumor therapy for the current recurrent or metastatic disease; * At least one measurable tumor lesion according to RECIST 1.1; * Eastern Cooperative Oncology Group performance status score of 0 or 1; * Life expectancy \> 12 weeks; * BMI≥16.0 kg/m2; * Adequate bone marrow, renal, and hepatic function; * Female patients of childbearing potential with a negative blood pregnancy test completed within 7 days before the first dose; * Patients should participate in the study voluntarily and sign informed consent. Exclusion Criteria: * Symptomatic, untreated, or actively progressing central nervous system (CNS) metastasis; * Other malignancies within the past 5 years; * Known hypersensitivity to any monoclonal antibodies or chemotherapy components; * Gastrointestinal abnormalities; * High risk of bleeding or fistula due to tumor invasion of adjacent organs, or existing esophageal/tracheal fistula; * Cardiovascular and cerebrovascular diseases; * Prior therapy with anti-angiogenic drugs or immunotherapy; Systemic therapy, investigational drugs, or live vaccines within 4 weeks prior to the first dose; Palliative radiotherapy within 2 weeks or major surgery within 28 days prior to enrollment; * Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage; * Presence of unresolved toxicities from prior anti-tumor therapy, defined as having not resolved to NCI CTCAE 5.0 Grade 0 or 1; * Active autoimmune disease or a history of autoimmune disease requiring systemic treatment; * Active infections, including severe infection (CTCAE \> Grade 2) within 4 weeks, active tuberculosis, or positive status for HIV, HBV, or HCV; * Pregnant or lactating women; * Female subjects of child-bearing potential and male subjects of reproductive capacity who do not agree to use contraceptive measures during the study and for 6 months after the end of the study; * Other conditions assessed by the investigator that would increase safety risks or interfere with the study results.